The CA-62 marker in a program of screening aimed at active detection of cancer in women of high onkorisk

Background. Globally, the increase in cancer rates is explained by improved diagnostic quality, an aging population, and the accumulation of unfavorable risk factors within the population. High achievements in early diagnosis of female cancer are based on expanding access to primary care and improving screening programs. Cancer is a heterogeneous group encompassing tumors with different origins, histological structures, clinical courses, and treatment outcomes, which necessitates selecting high-risk groups during routine medical examinations and periodic checkups, exploring new potential markers at this stage of population health monitoring. Aim. To investigate the role of the CA62 marker in screening programs for women at high risk of cancer. Materials and methods. The group of women with a high cancer risk was selected using automated questionnaires and amounted to 18.7 %. The main adverse risk factors were: age over 55 years combined with two external factors, including smoking/alcohol/poor diet, and physical inactivity; excess weight with a BMI 30 kg/m2; and a positive family history of cancer. Results. In 2023 and 2024, the CA-62 marker was analyzed in 1,099 women at high cancer risk. The analysis was performed using the CLIA-CA-62 chemiluminescence immunoassay (IVD). Values 5500 U/mL were found in 80 (7.27 %) women. A detailed examination of these patients revealed cancer in 5 (6.25 %) patients. Furthermore 8 (5.3 %) cases of cancer were found in the group of 150 women with reference values for the CA 62 marker. Conclusion. Thus, our analysis showed no benefit from using the CA-62 marker in screening programs for women with high-risk factors for cancer and requires further study.